Moderna, Inc. recently participated in the 5th LNP Formulation & Process Development Summit in Boston and scheduled a May 1, ...

The FDA is reviewing the first mRNA flu vaccine for adults 50 and older. Learn how this technology could lead to faster and more effective shots.

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will ...

The author writes, “The Food and Drug Administration has refused to review Moderna’s application for an mRNA flu vaccine, the company revealed Tuesday. The move is just the latest hostility toward ...

FDA reversal, patent relief, and mRESVIA risks show a commoditized market and lofty $20B valuation. See more here.

Just imagine, if the person responsible for evaluating vaccines at the FDA was required to have experience in that field ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice ...

Few corporate cautionary tales are as vivid as the rise and fall of Moderna Inc. During the pandemic, the company's mRNA vaccine was approved and distributed in record time, saving millions of lives ...

That raises the stakes for a second area of Moderna’s research. In a partnership with Merck, it’s been using its mRNA ...

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment ...

The European Medicines Agency just approved a new Moderna mRNA flu vaccine—after clinical data demonstrated strong protection for older adults. In the United States, the same technology is facing a ...